One of the most urgent requirements in breast cancer is the development of a blood-based test for early detection and prognosis. Previously published results found a significant difference between specific glycan levels in patients with advanced breast cancer and healthy controls. The aim of this investigation was to address a more clinically relevant problem, i.e., whether the measurement of specific glycans could identify women with aggressive disease at an early stage. In order to reduce potential bias in this study, blood samples from patients were collected, stored and analyzed in a similar manner. Agalactosyl biantennary glycans (FA2) and glycans containing the sialyl Lewis x epitope (A3F1G1 and A2F1G1) were measured using high throughput normal-phase highperformance liquid chromatography in combination with exoglycosidase digestions in sera from 52 patients with early breast cancer (21 with lymph node-negative and 20 with lymph node-positive disease) and 134 women with benign breast disease. The combined levels of the glycans were significantly higher in patients with lymph node metastases compared to women without these metastases. Lymph node status is the single most important determinant of survival in early stage breast cancer. As high levels of these glycans were associated with nodal metastases, their measurement may provide a new non-invasive approach to determining prognosis in women with newly diagnosed breast cancer.
Introduction
Several serum markers have been proposed for breast cancer including CA 15-3, carcinoembryonic antigen (CEA), tissue polypeptide antigen, tissue polypeptide specific antigen and the shed form of human epidermal growth factor receptor 2 (for review, see references Barak et al. 2004; Duffy 2006) . Of these, the most widely used in the clinic are CA 15-3 and CEA. Neither of these markers is elevated in patients with early breast cancer, limiting their use for early detection. Even in patients with advanced breast cancer, sensitivity is of the order of 70-80% (Barak et al. 2004; Duffy 2006) . Clearly, there is a need for more sensitive serum markers for breast cancer.
Glycosylation is one of the most common posttranslational modifications of the proteins; it can be N-and O-linked and is altered in cancer (Hakomori 1984) . The best characterized of these glycosylation changes are the increase in branching and levels of sialyl Lewis x (sLe x ) structures (Arnold et al. 2008 ). The sLe x epitope consists of a sialic acid residue α2,3-linked to galactose with fucose α1,3-linked to GlcNAc. SLe x is necessary for leukocyte extravasation and can be exploited by cancer cells to aid metastasis (Arnold et al. 2008) .
Aberrant protein glycosylation has been detected in various cancer types, including breast cancer (Kirmiz et al. 2007; Abd Hamid et al. 2008) . Indeed, growing evidence suggests that this altered glycosylation contributes to cancer progression (Kyselova et al. 2008) , especially metastasis (for review, see Saldova et al. 2008; Drake et al. 2009 ). Most of these findings, however, were based on tumor tissue and cell lines grown in vitro Drake et al. 2009 ). In order to exploit a potential role for these alterations in cancer diagnosis, it is necessary to detect them in a readily available fluid such as serum.
The aim of this study was to investigate whether levels of specific glycans in serum can detect aggressive disease in early breast cancer especially lymph node status, which is the single most important determinant of survival in early stage breast cancer. In order to minimize potential bias that might be associated with sample handling, blood samples were collected, stored and analyzed from patients and controls in a similar manner. We focused on the N-glycans containing the sLe x epitope (A3F1G1, A2F1G1) and FA2. A3F1G1, a triantennary glycan containing sLe x epitope, and agalactosyl biantennary glycans (FA2) were previously found to be elevated in patients with advanced breast and ovarian cancer (Saldova et al. 2007; Abd Hamid et al. 2008) . A2F1G1 is a biantennary glycan containing the sLe x epitope . SLe x and FA2 are linked to chronic inflammatory processes which are part of cancer pathology (Arnold et al. 2008) .
Results
N-Linked glycans from total serum glycoproteins of 52 patients with early breast cancer (21 with lymph node-negative and 20 with lymph node-positive disease) and 134 women with benign breast disease (Table I) were analyzed by normal-phase (NP)-high-performance liquid chromatography (HPLC) in combination with sequential digestion using an array of exoglycosidases.
The separation of the sLe x containing biantennary and triantennary glycans from other glycans was achieved by digesting with an array of exoglycosidases to segregate and quantify these potential markers. Following digestion with Arthrobacter ureafaciens sialidase (ABS) and β-galactosidase (BTG), the sialylated α1,3-fucosylated biantennary and triantennary sialylated structures were digested to form the α1,3-fucosylated monogalactosylated biantennary structure (A2F1G1) and α1,3-fucosylated monogalactosylated triantennary structure (A3F1G1). These digestion products elute at glucose units Fig. 1 . Typical NP-HPLC profiles of (A) undigested and (B) digested with Arthobacter ureafaciens sialidase (ABS) and bovine testis β-galactosidase (BTG) serum N-glycome from patient with benign breast disease, patient with lymph node-negative and patient with lymph node-positive breast cancer. All structures in each peak have been fully characterized previously by Royle et al. (2008) . Glycans FA2, A2F1G1 and A3F1G1 are highlighted.
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(GU) 7.1 and 7.5 as clear baseline-separated peaks allowing accurate quantification (Figure 1 ).
FA2 was quantified in the undigested profile at GU 5.9 ( Figure 1 ).
Combined levels of A3F1G1 + A2F1G1 + FA2 are significantly increased in patients with node-positive breast cancer Individual and combined N-glycan measurements were related to several pathological characteristics of the cancers and to patient age. The combined levels of A3F1G1 + A2F1G1 + FA2 were significantly higher in patients with node-positive compared to those with node-negative disease (Table II, Figure 2A ) and were well separated using principal component analysis (PCA) (the combined levels of the A3F1G1 + A2F1G1 + FA2 from patients with lymph node status positive and negative were chosen in an effort to see if these glycans could separate them, Figure 2B ). No significant change was found when correlating each individual marker separately (Table II) .
No significant correlations were found by comparing the distribution of the individual glycans A3F1G1, A2F1G1, FA2 or Levels of specific glycans in lymph node-positive cancer patients the combination of A3F1G1+A2F1G1 in serum from patients with early breast cancer and those with benign breast disease (Table III) . No significant relationship was found between any of the individual glycans or combination of glycans investigated and tumor size (Table SI) , tumor grade (Table SII) , histological type (Table SIII) , estrogen receptor (ER) status (Table SIV) and patient age at diagnosis (Table SV) .
Discussion
As mentioned in the Introduction above, there is an urgent need for more sensitive markers for early breast cancer diagnosis and prognosis. In a preliminary study, Abd Hamid et al. previously reported that glycans containing sLe x epitope were significantly increased in 18 advanced breast cancer patients with metastases (stage IV) compared to 18 healthy controls and positively correlate with disease progression and metastases (Abd .
Other investigators have also compared serum glycan levels in patients with breast cancer and control cohorts. Using mass spectrometry (MS), Kirmiz et al. (2007) measured glycan levels in four patients with a history of breast cancer and four with undefined diagnosis. Of the four patients with breast cancer, two had advanced disease. Of the other two, it was unclear if they had active disease or had already undergone surgical treatment for localized disease. Despite the limitations of this study, the authors stated that PCA appeared to separate the four cancers from the four controls. Kyselova et al. (2008) , also used MS to compare glycan levels in sera from breast cancer and controls. This study contained samples from 27 apparently healthy controls and 82 patients with breast cancer. Most of the patients with breast cancer had metastatic disease. Of the remainder, it was unclear if they had active disease. Using different statistical approaches, eight N-glycans were described as being characteristic of breast cancer.
The aim of this study was therefore to investigate whether levels of specific glycans, either alone or in combination, in serum can detect aggressive disease in early breast cancer. Unlike the above studies, all our samples were obtained from patients with localized or early breast cancer. Furthermore, blood was drawn prior to removal of the primary tumor, i.e., patients had active breast cancer. Most importantly, samples were obtained from clinically relevant groups, i.e., women with benign breast disease and lymph node-positive and node-negative early breast cancer. All samples were processed and stored identically.
Using this stringent approach, we found that the combined levels of these glycans were significantly higher in patients with lymph node-positive disease compared to those with lymph node-negative disease. The levels of these glycans alone did not show any significant difference; therefore, the combination of these glycans is important. It may reflect changes in fucosylation pathways (levels or activity of fucosyltransferases or availability of fucose as a nucleotide donor) as all these glycans contain fucose FA2 core fucose and A2F1G1 and A3F1G1 outer arm fucose.
Increased levels of sLe x suggest a change in the regulation of fucosyltransferases in the liver hepatocytes. To result in sLe x structures, the precursor core structure has to be sialylated first by α2,3 sialyltransferase forming sialyl-N-acetyl-D-lactosamine and then fucosylated by α(1,3/1,4) fucosyltransferases (Aubert et al. 2000; Magnani 2004 ). Increased levels of sLe x have been correlated with decreased expression of α1,2 fucosyltransferase, which competes with α2,3 sialyltransferase for the same substrate (Aubert et al. 2000) and increased expression of α(1,3/1,4) fucosyltransferases in human pancreatic cancer cells (Aubert et al. 2000) .
It should be pointed out that lymph node status is the most important prognostic determinant in patients with breast cancer. Since levels of serum A3F1G1 + A2F1G1 + FA2 were significantly elevated in node-positive patients in comparison to node-negative women, their measurement in serum may provide a new non-invasive approach to determining prognosis in patients with breast cancer as lymph node status is the single most important determinant of survival in early stage breast cancer.
The origin of the increased glycan levels in patients with node-positive vis-à-vis node-negative disease is unclear. One possibility is that they are produced by the lymph node metastases or possible occult metastatic disease. A more likely possibility, however, is that the increased levels are due to an acute phase response due to the nodal metastases, resulting in increased expression of abundant glycoproteins such as α1-acid glycoprotein, α1-antichymotrypsin or haptoglobin. These acute phase proteins contain high levels of the sLe x epitope that increase with disease progression and metastases in breast cancer (Abd . Indeed, increases in the sLe x epitope on acute phase proteins has been found in several cancers and chronic inflammatory conditions and also after stimulation with certain inflammatory cytokines (Arnold et al. 2008) . FA2, the agalactosyl biantennary glycan, comes predominantly from IgG and is increased in cancer and chronic inflammatory conditions (Arnold et al. 2008) . There is, however, no published evidence of an acute phase or inflammatory response in patients with locoregional metastatic spread to axillary lymph nodes.
In conclusion, the combined measurement of A3F1G1 + A2F1G1 + FA2 could be a valuable prognostic indicator in patients with early breast cancer. After further follow-up of our patients, we will test this possibility. 
Materials and methods

Serum samples and patient cohort
Blood samples were collected in 8.5 mL, BD vacutainer plastic CAT Plus "red-top" tubes (BD Biosciences, catalog number 367837) from consenting female patients who attended the Breast Clinic at St Vincent's University Hospital (SVUH), Dublin. These women were referred to the hospital because they had a breast lesion or lump that required further investigation. At the time of sampling, it was thus unclear whether the women had benign or malignant breast disease. Subsequent investigations, however, showed that of the 186 women investigated, 52 had breast cancer and 134 had benign breast disease. The blood samples were allowed to clot for up to 1 h and were then centrifuged at 2000 rpm for 10 min at room temperature. Sera were aliquoted into 60 µL volumes and stored in 0.5 mL plastic micro-tubes (Starstedt, catalog number 72-699) at −80°C. Samples were frozen within 2 h of being taken. Detailed clinicopathological characteristics of the cancers diagnosed are listed in Table I .
Release and purification of N-glycans from serum in gel block N-glycans were released from glycoproteins in the serum samples by digestion with N-glycosidase F (PNGase F, Roche Diagnostics GmbH, Manheim, Germany) in gel blocks as described previously (Royle et al. 2006) . Briefly, serum samples were reduced and alkylated, then set in sodium dodecyl sulfate-gel blocks and the N-glycans released with the addition of PNGase F.
Fluorescent labeling of N-glycans
Released N-glycans were fluorescently labeled with 2-aminobenzamide (2-AB) by reductive amination using a LudgerTag TM 2-AB labeling kit (Ludger Ltd., Abingdon, UK) (Royle et al. 2006 ) in a structurally unbiased manner, allowing accurate quantitative measurements and relative comparison between samples.
Exoglycosidase digestion of 2-AB-labeled N-glycans Exoglycosidase digestions followed by NP-HPLC, were used to confirm the structures of the N-glycans present in serum. The 2-AB-labeled glycans were digested in a volume of 10 µL for 18 h at 37°C in 50 mM sodium acetate buffer, pH 5.5, by sequentially adding the enzymes ABS (EC 3.2.1.18, 1 U/mL) and bovine testis BTG (EC 3.2.1.23, 1 U/mL). Enzymes were supplied by Glyko (Novato, CA). Following digestion, enzymes were removed by filtration trough proteinbinding EZ filters (Millipore Corporation, Bedford, MA) (Royle et al. 2006) .
HPLC
Labeled glycans were separated on NP-HPLC, which was performed using a TSK-Gel Amide-80 column (Anachem, Luton, UK) with a 35-47% gradient of 50 mM ammonium formate pH 4.4 Vs acetonitrile. The system was calibrated using an external standard of hydrolyzed and 2-AB-labeled glucose oligomers which formed a dextran ladder, as previously described (Royle et al. 2006) . The NP-HPLC glycan chromatogram was used to quantitatively compare glycan peaks. Individual peaks were normalized to the total peak area (whole glycome), and the percentage (%) area of the peaks was compared in all samples. N-glycan levels in patients with benign breast disease and breast carcinoma N-linked glycans from total serum glycoproteins of patients with benign and malignant breast disease were analyzed by NP-HPLC in combination with sequential exoglycosidase digestion and by making structural comparisons to a database of N-glycans (GlycoBase; http://glycobase.ucd.ie/cgi-bin/public/ glycobase.cgi) in a high throughput method as previously described . This method enables the analysis of glycan isoforms based on sequence and linkage (for example, core α1-6 fucosylation can be distinguished from α1-3 linked outer arm fucosylation), glycan size and linkage result in a specific elution position that can be converted to GUs using a dextran hydrolysate standard ladder .
We have used nomenclature according Royle et al. (2008) and Harvey et al. (2009) : all N-glycans have two core GlcNAcs; F at the start of the abbreviation indicates a core fucose α1-6 to inner GlcNAc; Man (x), number (x) of mannose on core GlcNAcs; A(x), number (x) of antenna (GlcNAc) on trimannosyl core; B, bisecting GlcNAc linked β1-4 to β1-3 mannose; F(x), number (x) of fucose linked α1-3 to antenna GlcNAc, G(x), number (x) of galactose on antenna; S(x), number of sialic acids on antenna. Symbol representations of glycans are as follows: GlcNAc, filled square; mannose, open circle; galactose, open diamond; fucose, diamond with a dot inside; beta linkage, solid line; alpha linkage, dotted line; 1-4 linkage, horizontal line; 1-3 linkage, (/); 1-2 linkage, vertical line; and 1-6 linkage, (\).
Statistical analysis
The Mann-Whitney U test and Kruskal-Wallis test (for continuous/nominal variables) were used to determine relationships between percentage N-glycan levels, and the clinicopathological characteristics of the patients. All statistics were calculated using SPSS version 12.0 (SPSS Inc., Chicago, IL). A P-value <0.05 was considered statistically significant. Multivariate statistics (PCA plot) was generated by using the SIMCA-P+ 12 software (Umetrics, Ascot, UK).
Supplementary data
Supplementary data for this article is available online at http://glycob.oxfordjournals.org/.
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